Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Mersana Therapeutics, Inc. Appoints Chief Scientific Officer, Timothy B. Lowinger, Ph.D.

Abstract:
Mersana, a cancer therapeutics company, announced today that Timothy B. Lowinger, Ph.D., has joined the company as Chief Scientific Officer.

Mersana Therapeutics, Inc. Appoints Chief Scientific Officer, Timothy B. Lowinger, Ph.D.

Cambridge, MA | Posted on February 12th, 2008

"We are thrilled that Tim is now a part of the Mersana team," said Julie A. Olson, President and CEO at Mersana. "His extensive leadership in oncology research and his experience with polymer-based drug systems are an ideal match for Mersana. In addition to the important impact he will have on our newest programs, his contributions toward advancing our lead product, XMT-1001, and our second product, XMT-1107, will be significant."

Dr. Lowinger has over fifteen years of experience in the pharmaceutical industry and brings a wealth of international experience to his new role in leading our Research team. From 1993 to 2007, Dr. Lowinger held a number of positions at Bayer Pharmaceuticals in the US, Germany, and Japan, where he contributed to the discovery of more than 15 pre-clinical and clinical candidates in a variety of indications. Most notably, he led the team that discovered and advanced Nexavar(R) (sorafenib), an anti-cancer agent that is approved for indications including renal and hepatocellular cancer, with Phase III studies underway in non-small-cell lung and other cancers. Later, as the VP and Department Head of Chemistry Research in West Haven, he managed a department of scientists in the disciplines of medicinal, analytical, computational, combinatorial and synthetic chemistry, focused on the discovery and clinical proof-of-concept of new therapeutics for the treatment of cancer, diabetes and obesity. He has most recently been VP of Chemistry and Pharmaceutical Sciences at Angiotech Pharmaceuticals where he managed a multidisciplinary team of scientists focused on developing polymer-based pharmaceutical products for local administration as well as medical devices incorporating pharmaceutical agents. Dr. Lowinger has a BSc in Chemistry and a Ph.D. in Organic Chemistry from the University of British Columbia in Vancouver, Canada.

####

About Mersana Therapeutics, Inc.
Mersana, a privately held, venture backed company, utilizes its proprietary nanotechnology platform to transform existing and experimental anti-cancer agents into new, patentable drugs with superior pharmaceutical properties. The key component of Mersana's platform is Fleximer(R), a novel, biodegradable and bio-inert polymer that can be chemically linked to small molecules and biologics. Mersana's pipeline includes XMT-1001, a Fleximer-camptothecin conjugate which is currently in Phase 1 clinical trials, and several preclinical oncology compounds. Mersana's investors include Fidelity Biosciences, ProQuest Investments, Rho Ventures, Harris & Harris Group and PureTech Ventures.

Fleximer(R) is a trademark of Mersana Therapeutics, Inc.

For more information, please click here

Contacts:
Mersana Therapeutics, Inc.
840 Memorial Drive
Cambridge, MA 02139

Tel: 617.498.0020
Fax: 617.498.0109

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Chains of nanogold – forged with atomic precision September 23rd, 2016

Tattoo therapy could ease chronic disease: Rice-made nanoparticles tested at Baylor College of Medicine may help control autoimmune diseases September 23rd, 2016

Nanotech Grants Options September 22nd, 2016

Coffee-infused foam removes lead from contaminated water September 21st, 2016

Nanomedicine

Tattoo therapy could ease chronic disease: Rice-made nanoparticles tested at Baylor College of Medicine may help control autoimmune diseases September 23rd, 2016

BBI Solutions launches innovative conjugate blocking technology that enhances signal intensity for lateral flow immunoassays September 20th, 2016

Iran to hold intl. school on application of nanomaterials in medicine September 20th, 2016

Graphene nanoribbons show promise for healing spinal injuries: Rice University scientists develop Texas-PEG to help knit severed, damaged spinal cords September 19th, 2016

Announcements

Chains of nanogold – forged with atomic precision September 23rd, 2016

Tattoo therapy could ease chronic disease: Rice-made nanoparticles tested at Baylor College of Medicine may help control autoimmune diseases September 23rd, 2016

Nanotech Grants Options September 22nd, 2016

Coffee-infused foam removes lead from contaminated water September 21st, 2016

Alliances/Trade associations/Partnerships/Distributorships

PHENOMEN is a FET-Open Research Project aiming to lay the foundations a new information technology September 19th, 2016

SEMI and MSIG Join Together in Strategic Association Partnership: MEMS & Sensors Industry Group Brings New MEMS and Sensors Community to SEMI to Increase Combined Member Value September 15th, 2016

Leti and Oberthur Technologies Partner to Explore New Solutions in Fast-growing Digital Era September 12th, 2016

Synopsys Joins GLOBALFOUNDRIES’ FDXcelerator Partner Program to Enable Innovative Designs Using the FD-SOI Process: Program Gives Synopsys Access to GLOBALFOUNDRIES’ FDX Portfolio and Provides Customers with Tools that Support the Differentiated Features of FD-SOI September 8th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic